2025-01-09 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational corporation that manufactures and sells medical devices, pharmaceuticals, and consumer packaged goods.

The cumulative return for JNJ is 21.43%, significantly lagging behind the S&P 500 (VOO) which has a cumulative return of 115.41%.  The difference is -94.0%, placing it at the 4.3rd percentile of its historical performance range relative to the S&P 500.  This indicates considerable underperformance compared to the broader market. The provided CAGR data shows fluctuating performance over the past several years, with some periods exceeding the market and others significantly underperforming. Note that the Alpha consistently measures close to zero, suggesting its returns largely mirror market movements (Beta is not explicitly provided in the table, but its close-to-zero Alpha suggests its beta is likely around 1).

**2. Recent Price Movement:**

* **Closing Price:** $142.27
* **5-day Moving Average:** $144.07
* **20-day Moving Average:** $145.09
* **60-day Moving Average:** $152.55

The current price is below all three moving averages, suggesting a downward trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 37.62 (Below 40, suggesting the stock might be oversold)
* **PPO:** 0.145 (Positive, but relatively low indicating weak momentum)
* **Delta_Previous_Relative_Divergence:** -2.1  (Indicating a recent short-term downtrend)
* **Expected Return:** -618.4% (This extremely negative figure warrants further investigation and clarification as it's unlikely to be accurate). The provided negative expected return is concerning and likely needs further investigation to confirm its validity.  It needs context in terms of how this figure was derived and what time horizon is used.

The current price of $142.27, coupled with negative indicators, does not suggest a dramatic recent upturn or downturn; it reflects a steady decline.


**4. Recent Earnings Analysis:**

The provided earnings data reveals some volatility:

* **EPS:** Fluctuates considerably across quarters, with a significant spike in Q3 2023 (10.32), likely an outlier.  Generally EPS is trending downward in the most recent quarters, though overall a year-over-year comparison needs more data.
* **Revenue:** Relatively stable around $22B with minor fluctuations.  While minor, there is a slight downtrend apparent in recent quarters.
* **Notable Beats or Misses:**  Without expected values, it's impossible to determine whether earnings have beaten or missed expectations.

**5. Financial Information Analysis:**

**Revenue and Profitability:** Revenue remains relatively consistent, showing only small changes quarter-over-quarter. Profit margins are consistently high (around 69%), indicating strong profitability.

**Capital and Profitability:** Equity shows some fluctuation but remains substantial.  ROE is highly variable. The exceptionally high ROE in Q3 2023 (36.54%) is an outlier, requiring further investigation to understand the contributing factors.  Generally, ROE sits in the low single digits.

**6. News and Recent Issues:**

No specific news or recent market outlook information is provided.  Analyst opinions and performance highlights are also not available within the given information.  More data is needed to properly assess this section.

**7. Overall Analysis:**

JNJ is currently underperforming the S&P 500 significantly.  Technical indicators point to an oversold condition, but weak momentum.  Recent earnings show relative stability in revenue but fluctuating EPS. While profit margins are high, the ROE volatility is a concern. The extremely negative projected return requires clarification.  More information regarding the news, analyst opinions, and a justification of the negative expected return is necessary to provide a more comprehensive assessment.  The overall picture suggests caution and further investigation is crucial before making investment decisions. The provided data shows some unusual figures which should be further examined for accuracy and additional context.

**8. Recommendations:**

Given the provided data, a more thorough investigation is needed to properly evaluate the future outlook for JNJ.  The significant underperformance compared to the S&P 500 and the highly volatile ROE and EPS readings necessitate deeper due diligence. Clarification on the -618.4% expected return and obtaining additional data such as analyst forecasts, market sentiment, and detailed financial statements are crucial before drawing concrete conclusions.  Without this information, providing specific investment recommendations is irresponsible.
